| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 07/13/2000 | WO2000040716A2 Soluble receptor br43x2 and methods of using them for therapy |
| 07/13/2000 | WO2000040714A2 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | WO2000040699A2 Astrocytes, their preparation and uses thereof |
| 07/13/2000 | WO2000040612A1 Insulin-like growth factor (igf) i mutant variants |
| 07/13/2000 | WO2000040600A1 Selective inhibitors of mmp-12 |
| 07/13/2000 | WO2000040597A1 Method and composition for angiogenesis inhibition |
| 07/13/2000 | WO2000040578A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 07/13/2000 | WO2000040576A2 Thiopyran compounds as inhibitors of mmp |
| 07/13/2000 | WO2000040552A1 Amidomalonamides and their use as inhibitors of matrix metalloproteinase |
| 07/13/2000 | WO2000040260A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 07/13/2000 | WO2000040258A1 Extracts of celery seed for the prevention and treatment of pain, inflammation and gastrointestinal irritation |
| 07/13/2000 | WO2000040243A1 Novel compounds |
| 07/13/2000 | WO2000040239A1 Compounds and methods |
| 07/13/2000 | WO2000040225A2 Inhibition of tnf activity |
| 07/13/2000 | WO2000040172A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | WO2000024897B1 Cell surface molecule-induced macrophage activation |
| 07/13/2000 | WO2000023091A3 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |
| 07/13/2000 | WO2000021986A3 Matrix-remodeling genes |
| 07/13/2000 | WO2000015248A3 Growth factor-containing composition for healing tissue damage |
| 07/13/2000 | WO2000015208A3 New use of immunosupressants for mmp-mediated diseases |
| 07/13/2000 | WO2000012517A9 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof |
| 07/13/2000 | WO2000010958A9 Vitamin d3 mimics |
| 07/13/2000 | WO2000008196A9 Urate oxidase |
| 07/13/2000 | WO1999058096A9 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| 07/13/2000 | CA2753331A1 Soluble receptor br43x2 and methods of using |
| 07/13/2000 | CA2358939A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 07/13/2000 | CA2357950A1 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | CA2357874A1 Cyclic compound |
| 07/13/2000 | CA2357146A1 Human cyclic nucleotide pdes |
| 07/13/2000 | CA2356966A1 Amidomalonamides and their use as inhibitors of matrix metalloproteinase |
| 07/13/2000 | CA2356919A1 Selective inhibitors of mmp-12 |
| 07/13/2000 | CA2356368A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | CA2355967A1 Astrocytes, their preparation and uses thereof |
| 07/13/2000 | CA2354194A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 07/12/2000 | EP1018517A2 Binding agents to CD23 for treatment of inflammatory, autoimmune or allergic diseases |
| 07/12/2000 | EP1017980A2 Methods of the identification of pharmaceutically active compounds |
| 07/12/2000 | EP1017807A1 Osf2/cbfa1 compositions and methods of use |
| 07/12/2000 | EP1017713A1 CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS |
| 07/12/2000 | EP1017697A1 MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 07/12/2000 | EP1017681A1 Hydrazono-benzazulene derivatives, pharmaceutical compositions and intermediates |
| 07/12/2000 | EP1017680A1 Tricyclic compounds, preparation method and said method intermediates, application as medicines and pharmaceutical compositions containing same |
| 07/12/2000 | EP1017667A1 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies |
| 07/12/2000 | EP1017664A1 C3a receptor ligands |
| 07/12/2000 | EP1017423A1 Cloning pigs using donor nuclei from differentiated cells |
| 07/12/2000 | EP1017387A1 Vitronectin receptor antagonist |
| 07/12/2000 | EP1017385A1 USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 |
| 07/12/2000 | EP1017378A1 Amide derivatives for the treatment of diseases mediated by cytokines |
| 07/12/2000 | EP1017377A2 Use of 6, 7-substituted 2-aminotetralines for the treatment of cytokine mediated inflammatory conditions |
| 07/12/2000 | CN1259956A Novel 4-Halogenated steroids prepn. method and intermediates, application as medicines and pharmaceutical compositions contg. same |
| 07/12/2000 | CN1259951A Novel pharmaceutically useful compounds |
| 07/12/2000 | CN1259948A 6,7-disubstituted-4-aminopyrido [2,3-D] pyrimidine compounds |
| 07/12/2000 | CN1259947A 2-aryl-naphthyridin-4-ones as antitumor agent |
| 07/12/2000 | CN1259940A Crystalline roxifiban |
| 07/12/2000 | CN1259376A Medicinal liquid for treating bone fracture |
| 07/12/2000 | CN1259370A Medicinal powder for relieving pain of bone bi-syndrome |
| 07/12/2000 | CN1259369A Medicine for treating rigid spine inflammation and prepn. method thereof |
| 07/12/2000 | CN1259346A Optically pure compound as medicinal use |
| 07/12/2000 | CN1054291C Plaster for treating spur and cervical spondylopathy |
| 07/12/2000 | CN1054285C Quick bone-setting medicinal powder |
| 07/11/2000 | US6087392 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides |
| 07/11/2000 | US6087381 Pyrazole derivatives as p38 kinase inhibitors |
| 07/11/2000 | US6087378 The active benzo(b)thiophene compounds for treating osteoporosis and cardiovascular disorders, especially hyperlipidemia |
| 07/11/2000 | US6087338 Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin |
| 07/11/2000 | US6087172 For treatment of rheumatoid arthritis by suppression of interleukin-15 production |
| 07/11/2000 | US6087150 Interleukin-1 β converting enzyme like apoptosis protease-3 and 4 |
| 07/11/2000 | US6087122 Polynucleotide sequence which codes a mammalian polypeptide synthetases; for diagnosis, evaluation, prevention, and treatment of physiological defects |
| 07/11/2000 | US6086918 Releasing peptide active agent, with ph lowering agent and an absorption enhancer into patient's intestine through mouth and stomach under protection of an acid resistant vehicle which prevents contact between stomach protease and peptide |
| 07/06/2000 | WO2000039311A1 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 |
| 07/06/2000 | WO2000039308A1 Ikk3 kinase |
| 07/06/2000 | WO2000039278A2 Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| 07/06/2000 | WO2000039275A2 Multiple shear stress responsive elements (ssre) and methods of use thereof |
| 07/06/2000 | WO2000039176A1 Hydrophilic ampholytic polymer |
| 07/06/2000 | WO2000039136A2 Human brainiac-5 |
| 07/06/2000 | WO2000039120A2 Compounds and methods for modulation of estrogen receptors |
| 07/06/2000 | WO2000039116A1 Aminopyrazole derivatives |
| 07/06/2000 | WO2000039115A1 Protease inhibitors |
| 07/06/2000 | WO2000039114A2 Substituted oximes and hydrazones as neurokinin antagonists |
| 07/06/2000 | WO2000039101A1 Pyrimidine compounds |
| 07/06/2000 | WO2000039091A1 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives |
| 07/06/2000 | WO2000039089A1 3-azabicyclo[3.1.0.] hexane derivatives as opiate receptors ligands |
| 07/06/2000 | WO2000039077A2 Thyroid receptor ligands |
| 07/06/2000 | WO2000039070A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| 07/06/2000 | WO2000038707A1 Method for the treatment of bone loss |
| 07/06/2000 | WO2000038701A1 Use of unsaponifiable matters of vegetable oils for preparing a medicine |
| 07/06/2000 | WO2000038694A1 Medicinal compositions for treating osseous lesion in multiple myeloma |
| 07/06/2000 | WO2000038687A1 Protease inhibitors |
| 07/06/2000 | WO2000038681A1 Liposomic niflumic acid - new transdermal anti-inflammatory medicine |
| 07/06/2000 | WO2000038674A1 COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR |
| 07/06/2000 | WO2000038659A1 Transdermal drug delivery system |
| 07/06/2000 | WO2000038653A1 Improved formulation for topical non-invasive application in vivo |
| 07/06/2000 | WO2000021910A3 1,2-disubstituted cyclopropanes |
| 07/06/2000 | WO2000020591A3 Tgf-beta superfamily mutant members, including morphogenic proteins |
| 07/06/2000 | WO2000018954A3 Use of pex in the treatment of metabolic bone diseases |
| 07/06/2000 | WO2000018352A3 A method for treating inflammatory diseases by administering a thrombin inhibitor |
| 07/06/2000 | WO2000017222A8 31 human secreted proteins |
| 07/06/2000 | WO2000015770A3 Human serine/threonine protein kinases |
| 07/06/2000 | WO1999052514A3 Pharmaceutical composition and combination preparation for immunosuppressive therapy |
| 07/06/2000 | CA2358315A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| 07/06/2000 | CA2358094A1 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 |
| 07/06/2000 | CA2357765A1 Liposomic niflumic acid - new transdermal anti-inflammatory medicine |